Equillium triples clinical pipeline with $329m Bioniz takeover
alopecia, Bioniz, coeliac disease, Equillium, graft versus host disease, immunology, lymphoma, M&A
0 Comment
graft versus host disease
BMS’ Orencia gets FDA nod for GvHD thanks to real-world data
Bristol-Myers Squibb, fda, graft versus host disease, Orencia, prevention, regulatory approval
0 Comment
Sanofi snaps up Kadmon and its transplant drug Rezurock
belumosudil, graft versus host disease, Kadmon, M&A, Sanofi
0 Comment
Shock as FDA rejects Mesoblast’s Ryoncil in paediatric graft versus host disease
cancer, graft versus host disease, Mesoblast, Ryoncil
0 Comment
Kadmon preps filing for GVHD drug belumosudil after phase 3 win
belumosudil, bone marrow transplant, graft versus host disease, immunology, Kadmon, Oncology
0 Comment
Kiadis sheds half its staff as lead cell therapy bombs
cell therapy, graft versus host disease, Kiadis Pharma
0 Comment
Janssen/AbbVie drug approved in graft-versus-host disease
AbbVie, cancer, graft versus host disease, Johnson & Johnson
0 Comment
First use for Imbruvica outside blood cancer.
Imbruvica granted fourth Breakthrough status
AbbVie, graft versus host disease, GVHD, ibrutinib
0 Comment
The drug is also granted Orphan Drug Designation by the FDA.